Every AI newsletter, investors ask on the investor interaction platform: are there any current medical products or projects
Hhc Changzhou Corp(301061) ( Hhc Changzhou Corp(301061) . SZ) said on the investor interaction platform on April 23 that in the United States, the company is a production-oriented enterprise approved by the FDA (food and Drug Administration) to produce some medical products. In recent years, the development of the company in this field has been relatively stable. Entering China’s health care industry is one of the company’s important development strategies. In October 2021, ingenuity medical, which serves China’s health care market, began to be established in Changzhou headquarters. The first batch of products independently designed and developed include smart beds in health care institutions, multi position rehabilitation treatment beds, home care smart beds, etc. While designing and developing its own products, ingenuity medical actively explores cooperation with other Chinese and foreign professional institutions, including Chinese downstream customers (such as nursing apartments and rehabilitation hospitals), Israeli research institutions, etc.
